Incadronic acid

DB06255

small molecule experimental

Deskripsi

Incadronate, or YM-175,A202769 is a nitrogen containing bisphosphonate. Along with being investigated to treat hypercalcemia of malignancy,A202862 it has also been investigated in the treatment of myeloma, leukemia, and other cancers.A14426,A14431,A14427,A202769

Incadronic acid was first described in the literature in 1991.A202289

Struktur Molekul 2D

Berat 287.189
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) Incadronate has a biexponential half life. The T<sub>1/2</sub>? is 0.26-0.40h and the T<sub>1/2</sub>? is 1.58-1.98h.[A14433]
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Incadronate is not metabolized in rats.A202862

Rute Eliminasi

Incadronate is 55.1-69.5% eliminated in the urine as the unchanged parent drug.A14433

Interaksi Obat

330 Data
Deferasirox The risk or severity of gastrointestinal bleeding and gastrointestinal ulceration can be increased when Incadronic acid is combined with Deferasirox.
Bevacizumab The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Bevacizumab is combined with Incadronic acid.
Lenalidomide The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Lenalidomide is combined with Incadronic acid.
Thalidomide The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Thalidomide is combined with Incadronic acid.
Sunitinib The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Sunitinib is combined with Incadronic acid.
Ranibizumab The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Ranibizumab is combined with Incadronic acid.
Fumagillin The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Fumagillin is combined with Incadronic acid.
Resveratrol The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Resveratrol is combined with Incadronic acid.
Halofuginone The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Halofuginone is combined with Incadronic acid.
Anecortave acetate The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Anecortave acetate is combined with Incadronic acid.
Endostatin The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Endostatin is combined with Incadronic acid.
Semaxanib The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Semaxanib is combined with Incadronic acid.
Squalamine The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Squalamine is combined with Incadronic acid.
Pazopanib The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Pazopanib is combined with Incadronic acid.
Volociximab The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Volociximab is combined with Incadronic acid.
TNP-470 The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when TNP-470 is combined with Incadronic acid.
Pomalidomide The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Pomalidomide is combined with Incadronic acid.
Roquinimex The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Roquinimex is combined with Incadronic acid.
Endostar The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Endostar is combined with Incadronic acid.
Trebananib The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Trebananib is combined with Incadronic acid.
Anecortave The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Anecortave is combined with Incadronic acid.
Beloranib The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Beloranib is combined with Incadronic acid.
Brolucizumab The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Brolucizumab is combined with Incadronic acid.
Pantoprazole The therapeutic efficacy of Incadronic acid can be decreased when used in combination with Pantoprazole.
Omeprazole The therapeutic efficacy of Incadronic acid can be decreased when used in combination with Omeprazole.
Lansoprazole The therapeutic efficacy of Incadronic acid can be decreased when used in combination with Lansoprazole.
Esomeprazole The therapeutic efficacy of Incadronic acid can be decreased when used in combination with Esomeprazole.
Rabeprazole The therapeutic efficacy of Incadronic acid can be decreased when used in combination with Rabeprazole.
Dexlansoprazole The therapeutic efficacy of Incadronic acid can be decreased when used in combination with Dexlansoprazole.
Dexrabeprazole The therapeutic efficacy of Incadronic acid can be decreased when used in combination with Dexrabeprazole.
Ilaprazole The therapeutic efficacy of Incadronic acid can be decreased when used in combination with Ilaprazole.
Icosapent The risk or severity of gastrointestinal bleeding can be increased when Icosapent is combined with Incadronic acid.
Mesalazine The risk or severity of nephrotoxicity and hypocalcemia can be increased when Mesalazine is combined with Incadronic acid.
Indomethacin The risk or severity of gastrointestinal bleeding can be increased when Indomethacin is combined with Incadronic acid.
Nabumetone The risk or severity of gastrointestinal bleeding can be increased when Nabumetone is combined with Incadronic acid.
Ketorolac The risk or severity of gastrointestinal bleeding can be increased when Ketorolac is combined with Incadronic acid.
Tenoxicam The risk or severity of gastrointestinal bleeding can be increased when Tenoxicam is combined with Incadronic acid.
Celecoxib The risk or severity of gastrointestinal bleeding can be increased when Celecoxib is combined with Incadronic acid.
Tolmetin The risk or severity of gastrointestinal bleeding can be increased when Tolmetin is combined with Incadronic acid.
Rofecoxib The risk or severity of gastrointestinal bleeding can be increased when Rofecoxib is combined with Incadronic acid.
Piroxicam The risk or severity of gastrointestinal bleeding can be increased when Piroxicam is combined with Incadronic acid.
Fenoprofen The risk or severity of gastrointestinal bleeding can be increased when Fenoprofen is combined with Incadronic acid.
Valdecoxib The risk or severity of gastrointestinal bleeding can be increased when Valdecoxib is combined with Incadronic acid.
Diclofenac The risk or severity of gastrointestinal bleeding can be increased when Diclofenac is combined with Incadronic acid.
Sulindac The risk or severity of gastrointestinal bleeding can be increased when Sulindac is combined with Incadronic acid.
Flurbiprofen The risk or severity of gastrointestinal bleeding can be increased when Flurbiprofen is combined with Incadronic acid.
Etodolac The risk or severity of gastrointestinal bleeding can be increased when Etodolac is combined with Incadronic acid.
Mefenamic acid The risk or severity of gastrointestinal bleeding can be increased when Mefenamic acid is combined with Incadronic acid.
Naproxen The risk or severity of gastrointestinal bleeding can be increased when Naproxen is combined with Incadronic acid.
Sulfasalazine The risk or severity of gastrointestinal bleeding can be increased when Sulfasalazine is combined with Incadronic acid.
Phenylbutazone The risk or severity of gastrointestinal bleeding can be increased when Phenylbutazone is combined with Incadronic acid.
Meloxicam The risk or severity of gastrointestinal bleeding can be increased when Meloxicam is combined with Incadronic acid.
Carprofen The risk or severity of gastrointestinal bleeding can be increased when Carprofen is combined with Incadronic acid.
Diflunisal The risk or severity of gastrointestinal bleeding can be increased when Diflunisal is combined with Incadronic acid.
Salicylic acid The risk or severity of gastrointestinal bleeding can be increased when Salicylic acid is combined with Incadronic acid.
Meclofenamic acid The risk or severity of gastrointestinal bleeding can be increased when Meclofenamic acid is combined with Incadronic acid.
Acetylsalicylic acid The risk or severity of gastrointestinal bleeding can be increased when Acetylsalicylic acid is combined with Incadronic acid.
Oxaprozin The risk or severity of gastrointestinal bleeding can be increased when Oxaprozin is combined with Incadronic acid.
Ketoprofen The risk or severity of gastrointestinal bleeding can be increased when Ketoprofen is combined with Incadronic acid.
Balsalazide The risk or severity of gastrointestinal bleeding can be increased when Balsalazide is combined with Incadronic acid.
Ibuprofen The risk or severity of gastrointestinal bleeding can be increased when Ibuprofen is combined with Incadronic acid.
Olsalazine The risk or severity of nephrotoxicity and hypocalcemia can be increased when Olsalazine is combined with Incadronic acid.
Lumiracoxib The risk or severity of gastrointestinal bleeding can be increased when Lumiracoxib is combined with Incadronic acid.
Magnesium salicylate The risk or severity of gastrointestinal bleeding can be increased when Magnesium salicylate is combined with Incadronic acid.
Salsalate The risk or severity of gastrointestinal bleeding can be increased when Salsalate is combined with Incadronic acid.
Choline magnesium trisalicylate The risk or severity of gastrointestinal bleeding can be increased when Choline magnesium trisalicylate is combined with Incadronic acid.
Antrafenine The risk or severity of gastrointestinal bleeding can be increased when Antrafenine is combined with Incadronic acid.
Aminophenazone The risk or severity of gastrointestinal bleeding can be increased when Aminophenazone is combined with Incadronic acid.
Antipyrine The risk or severity of gastrointestinal bleeding can be increased when Antipyrine is combined with Incadronic acid.
Tiaprofenic acid The risk or severity of gastrointestinal bleeding can be increased when Tiaprofenic acid is combined with Incadronic acid.
Etoricoxib The risk or severity of gastrointestinal bleeding can be increased when Etoricoxib is combined with Incadronic acid.
Taxifolin The risk or severity of gastrointestinal bleeding can be increased when Taxifolin is combined with Incadronic acid.
Oxyphenbutazone The risk or severity of gastrointestinal bleeding can be increased when Oxyphenbutazone is combined with Incadronic acid.
Licofelone The risk or severity of gastrointestinal bleeding can be increased when Licofelone is combined with Incadronic acid.
Nimesulide The risk or severity of gastrointestinal bleeding can be increased when Nimesulide is combined with Incadronic acid.
Benoxaprofen The risk or severity of gastrointestinal bleeding can be increased when Benoxaprofen is combined with Incadronic acid.
Metamizole The risk or severity of nephrotoxicity and hypocalcemia can be increased when Metamizole is combined with Incadronic acid.
Zomepirac The risk or severity of gastrointestinal bleeding can be increased when Zomepirac is combined with Incadronic acid.
Cimicoxib The risk or severity of gastrointestinal bleeding can be increased when Cimicoxib is combined with Incadronic acid.
Lornoxicam The risk or severity of gastrointestinal bleeding can be increased when Lornoxicam is combined with Incadronic acid.
Aceclofenac The risk or severity of gastrointestinal bleeding can be increased when Aceclofenac is combined with Incadronic acid.
Zaltoprofen The risk or severity of gastrointestinal bleeding can be increased when Zaltoprofen is combined with Incadronic acid.
Azapropazone The risk or severity of gastrointestinal bleeding can be increased when Azapropazone is combined with Incadronic acid.
Parecoxib The risk or severity of gastrointestinal bleeding can be increased when Parecoxib is combined with Incadronic acid.
Salicylamide The risk or severity of gastrointestinal bleeding can be increased when Salicylamide is combined with Incadronic acid.
Kebuzone The risk or severity of gastrointestinal bleeding can be increased when Kebuzone is combined with Incadronic acid.
Isoxicam The risk or severity of gastrointestinal bleeding can be increased when Isoxicam is combined with Incadronic acid.
Indoprofen The risk or severity of gastrointestinal bleeding can be increased when Indoprofen is combined with Incadronic acid.
Ibuproxam The risk or severity of gastrointestinal bleeding can be increased when Ibuproxam is combined with Incadronic acid.
Floctafenine The risk or severity of gastrointestinal bleeding can be increased when Floctafenine is combined with Incadronic acid.
Fenbufen The risk or severity of gastrointestinal bleeding can be increased when Fenbufen is combined with Incadronic acid.
Etofenamate The risk or severity of gastrointestinal bleeding can be increased when Etofenamate is combined with Incadronic acid.
Epirizole The risk or severity of gastrointestinal bleeding can be increased when Epirizole is combined with Incadronic acid.
Benzydamine The risk or severity of gastrointestinal bleeding can be increased when Benzydamine is combined with Incadronic acid.
Dexibuprofen The risk or severity of gastrointestinal bleeding can be increased when Dexibuprofen is combined with Incadronic acid.
Dexketoprofen The risk or severity of gastrointestinal bleeding can be increased when Dexketoprofen is combined with Incadronic acid.
Droxicam The risk or severity of gastrointestinal bleeding can be increased when Droxicam is combined with Incadronic acid.
Tolfenamic acid The risk or severity of gastrointestinal bleeding can be increased when Tolfenamic acid is combined with Incadronic acid.
Firocoxib The risk or severity of gastrointestinal bleeding can be increased when Firocoxib is combined with Incadronic acid.
Clonixin The risk or severity of gastrointestinal bleeding can be increased when Clonixin is combined with Incadronic acid.

Target Protein

Farnesyl pyrophosphate synthase FDPS
Caspase-3 CASP3
Caspase-4 CASP4
Caspase-7 CASP7

Referensi & Sumber

Artikel (PubMed)
  • PMID: 12742232
    Iguchi T, Miyakawa Y, Yamamoto K, Kizaki M, Ikeda Y: Nitrogen-containing bisphosphonates induce S-phase cell cycle arrest and apoptosis of myeloma cells by activating MAPK pathway and inhibiting mevalonate pathway. Cell Signal. 2003 Jul;15(7):719-27.
  • PMID: 17233845
    Ishikawa C, Matsuda T, Okudaira T, Tomita M, Kawakami H, Tanaka Y, Masuda M, Ohshiro K, Ohta T, Mori N: Bisphosphonate incadronate inhibits growth of human T-cell leukaemia virus type I-infected T-cell lines and primary adult T-cell leukaemia cells by interfering with the mevalonate pathway. Br J Haematol. 2007 Feb;136(3):424-32.
  • PMID: 16236616
    Ochiai N, Yamada N, Uchida R, Fuchida S, Okano A, Okamoto M, Ashihara E, Inaba T, Shimazaki C: Nitrogen-containing bisphosphonate incadronate augments the inhibitory effect of farnesyl transferase inhibitor tipifarnib on the growth of fresh and cloned myeloma cells in vitro. Leuk Lymphoma. 2005 Nov;46(11):1619-25.
  • PMID: 9208339
    Usui T, Oiso Y, Tomita A, Ogata E, Uchida T, Ikeda K, Watanabe T, Higuchi S: Pharmacokinetics of incadronate, a new bisphosphonate, in healthy volunteers and patients with malignancy-associated hypercalcemia. Int J Clin Pharmacol Ther. 1997 Jun;35(6):239-44.
  • PMID: 1800007
    Kawashima H, Nagao Y, Ishitobi Y, Kinoshita H, Fukushima S: Bisphosphonates increase serum 1,25-dihydroxyvitamin D in rats via stimulating renal production of the hormone. Contrib Nephrol. 1991;91:140-5. doi: 10.1159/000420170.
  • PMID: 23044853
    Miwa A, Takezako N, Hayakawa H, Hayakawa M, Tominaga S, Yanagisawa K: YM-175 induces apoptosis of human native monocyte-lineage cells via inhibition of prenylation. Am J Hematol. 2012 Dec;87(12):1084-8. doi: 10.1002/ajh.23328. Epub 2012 Oct 9.
  • PMID: 9179988
    Usui T, Tanaka S, Sonoda T, Ozawa Y, Teramura K, Nakamura E, Watanabe T, Higuchi S: Drug disposition of incadronate, a new bisphosphonate, in rats with bone metastases. Xenobiotica. 1997 May;27(5):479-87. doi: 10.1080/004982597240442.
  • PMID: 18214569
    Russell RG, Watts NB, Ebetino FH, Rogers MJ: Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008 Jun;19(6):733-59. doi: 10.1007/s00198-007-0540-8.
Menampilkan 8 dari 9 artikel.

Contoh Produk & Brand

Produk: 0 • International brands: 2
International Brands
  • Bisphonal — Astellas
  • Yin Fu — Renfu Pharmaceutical

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul